The effect of co-inoculation of membrane matrix, Matrigel and two human breast cancer cell lines, was (Cornil et al., 1989; Fu et al., 1991 Fu et al., , 1992 (Elledge et al., 1992) and has been reported to be an important prognostic factor in node-negative breast ancer (Pavelic et al., 1992). Stable and exclusive c-erbB-2 overexpression by malignant cells (Niehans et al., 1993) and profound effects of signal transduction through the c-ErbB-2 pathway (Harwerth et al., 1993; Lupu and Lippman 1993) (Boston, MA, USA). These mice lack natural killer cell activity owing to the beige (bg) mutation, are athymic owing to the nude mutation (nu) and have a lack of T cell-independent B cells because of their X-linked immun deficiency. The animals were kept in isolator cages which were changed twice weekly. They were Correspondence: H-J van Slooten,
. For a number of tumour types, such as colon cancer, melanoma and pancreatic cancer, orthotopic implantation of primary tumours in these animals has been reported to improve significntly both take rate and expression of metastatc phenotype (Cornil et al., 1989; Fu et al., 1991 Fu et al., , 1992 (Fogh et al., 1977) . At present, in vivo/in vitro studies of hormone-dependent breast cancer largely depend on the MCF-7, T47D and ZR-75-1 cell lines (Shafie and Liotta, 1980, Leung and Shiu, 1981; Weckbecker et al., 1992; Yue and Brodie, 1993) . These (Horgan et al., 1987; Fridman et al., 1990 Fridman et al., , 1991 Fridman et al., , 1992 Chung, 1991; Pretlow et al., 1991; Albini et al., 1992; Noel et al., 1992; Paaniti et al., 1992; Mehta et al., 1993; Sterling-Levis et al., 1993; Topley et al., 1993; Yue and Brodie 1993; Bao et al., 1994) . (Elledge et al., 1992) and has been reported to be an important prognostic factor in node-negative breast ancer (Pavelic et al., 1992) . Stable and exclusive c-erbB-2 overexpression by malignant cells (Niehans et al., 1993) and profound effects of signal transduction through the c-ErbB-2 pathway (Harwerth et al., 1993; Lupu and Lippman 1993) The DNA index from frozen sections and paraffin-embedded tissue was determined using the methods described by Vindelov et al. (1983) and Hedley et al. (1983) . Chicken red blood cells (CRBCs) were added to each sample as a reference. The DNA index (defined as human aneuploid G0.//human diploid Goll) of BT-474 cells was calculated using the ratio human diploid G11 peak/CRBC. Samples were measured on a FACScan flow cytometer (Becton Dickinson) and analysed using MODFIT software (Verity Software House, Topsham, ME, USA).
Immunohistochemistry
To compare expression of antigens in BT-474 tumours with flow cytometical analysis of the cell line, frozen sections of tumour were fixed according to the protocol used for flow cytometry. Standard DAB staining with biotinylated goat anti-mouse bridging antibody (Becton Dickinson) and streptavidin-biotinylated horseradish peroxidase complex (Becton Dickinson) was used for detection of bound primary antibodies. Methyl green dye was used for background staining.
ER, Ki-67, PCNA and keratin staining ofparaffin-embedd tissue Two micron praffin sections were mounted on Starfrost tissue section slides (Knittel Gliser, Braunschweig, Germany) , dried overnight at room temperature and deparaffinisd Subsequently, ER was stained usng the Abbott kit (Abbott Diagnostics Division) and Novocastra kit (Novocastra Laboratories, Newcastle upon Tyne, UK). For Ki-67, proliferating cel nuclear antigen (PCNA) and keratin staining endogenous peroxidase was blocked with methanol-0.3% hydrogen peroxide (20 min). Sections were boied in 2 x SSC* (20 mi; (Table I) .
Because co-inoculation of various types of tumour cells with fibroblasts has been reported to increase take rate in immune-deficient mice, two groups of four animals were inoculated with an equal mixture of tumour cdls and tuLmour-derived fibroblasts in Matrigel (Table I and Figure  1c ), resulting in two progressively growing (Figure 4) . Furthermore, 32% of cells growing in vitro expressed vimentin (Figure 4) , and a population of 32% of cells expressed lower levels of Ep-CAM (Figure 4) Cell cycle kinetics: comparison of tumours growing in the neck and in the mammary fat pad We investigated whether differences in growth rate between tumours growing in the neck and mammary fat pad were correlated with differences in growth fraction or apoptotic fraction. These fractions were determined by immunohistochemistry with the MIB-1 antibody against Ki-67 and in situ end-labelling of DNA strand breaks respectively. Growth fractions were quantitated by counting a total of 1000 cells in every section. Apoptotic fractions were determined with an automated image analysis system. Surprisingly, no significant differences were found in growth fractions or apoptotic fractions of tumours growing in the neck compared with the mammary fat pad of the same mouse (Table IV) .
Dimss
While useful xenotransplantation models have been developed for other primary tumours Cornil et al., 1989; Fu et al., 1991 Fu et al., , 1992 , this approach remains very difficult for primary hormone-dependent breast cancer. The only hormone-responsive cell lines for which successful xenotransplantation has been described are the MCF-7, ZR-75-1 and T-47D cell lines (Shafie and Liotta, 1980; Leung and Shiu, 1981; Weckbecker et al., 1992; Yue and Brodie, 1993) IgG2a ND 'Summarised from flow cytometric data (Figure 4) . b32% of the cells expressed lower or higher levels respectively. 9Determined on paraffin sections. dResults stated in text. ND, not determined. Antigen expression in frozen sections and cell lines was scored semiquantitatively, scores ranging from negative (-) to high expression ( + 5) . +1 is +, +5is +++++.
imately 1000 cells results in formation of tumours. Because the main component of Matrigel is the basement membrane protein laminin, the capability of BT-474 cells to bind to this protien using receptors such as 4f4-integrin, is likely to contribute to this effect of Matrigel on tumorigenicity. It has been hypothesised that Matrigel, and especially proteolytic fragments of laminin, plays a role in stimulating angiogenesis (Fridman et al., 1992) , and therefore is responsible for the outgrowth of inoculated tumour cells. Furthermore, matrixassociated growth factors (e.g. fibroblast growth factors; tissue plasminogen activator) within Matrigel may also enhance tumorigemncity.
Although it does not seem to be an absolute requirement, oestrogen supplementation greatly enhances tumorigenicity. Removal of oestrogen pellets from animals with established BT-474 tumours resulted in tumour regression accompanied by marked apoptosis (GT Colbern, personal communication), indicating that BT474 tumours are dependent on oestrogen for their growth. Similarly, oestrogen-dependent MCF-7 cells have been reported to retain the ability to activate a programmed cell death pathway following oestrogen ablation (Kyprianou et al., 1991) . Our findings are therefore consistent with the hypothesis that oestrogen not only stimulates proliferation, but may also serve as a strong survival factor for breast cancer cells. Addition of fibroblasts, reported to increase tumongemcity of several cell lines in immune-deficient mice (Horgan et al., 1987; Chung, 1991; Noel et al., 1992) , had no additional effect. A number of reports described an increased take rate of breast tumour cells after inoculation into the mammary fat pad (Miller et al., 1981; White et al., 1982; Miller and Mclnerney, 1988; Price et al., 1990; Elliott et al., 1992) , but in the present study we observed a higher take and growth rate of BT-474 cells in the neck region than in the mammary fat pad. Because no difference was observed in expression of the cellular proliferation marker Ki-67 between two tumours derived from the neck and mammary fat pad respectively, a difference in cell loss was likely to be responsible for this phenomenon. However, we did not find a significant difference in the number of apoptotic cells detected by in situ end-labelling of DNA strand breaks, making it difficult to explain observed differences in tumour growth rate. We cannot exclude the possibility that physical differences such as subcutaneous The BT-474 cell line was originally reported to be ER negative, but more recent studies have reported it to be ER positive, as detected by radioligand-binding assay (Koga et al., 1990; Lupu and Lippman, 1993 (Tsunoda et al., 1992) .
The high rate of apoptosis, even in rapidly growing BT-474 tumours with high PCNA and Ki-67 indices, prompted us to analyse some factors that could be involved in this process.
The product of the c-myc oncogene has been reported to drive both proliferation and apoptosis (Evan and Littlewood, 1993) , whereas increased expression of the bcl-2 gene could possibly enhance survival of cells otherwise doomed to die. In many cell types, Bcl-2 has been reported to counteract the induction of cell death by various treatments (Kamesaki et al., 1993; Reed, 1994) , including apoptosis induced by overexpression of c-myc (Bissonnette et al., 1992) . The intermediate lvel of Bcl-2 expression in BT-474 cells raises the question of whether the level of Bcl-2 is not sufficient to inhibit apoptosis effectively in BT-474 tumours, or whether this type of apoptotic cell death is simply not modulated by Bcl-2, but by one of its recently discovered variants (Boise et al., 1993; Oltvai et al., 1993) .
Another factor possibly involved in the induction of apoptosis is the product of the p53 tumour-suppressor gene. Mounting evidence shows that wild-type p53 protein is important for the induction of apoptosis in cells with a signifant amount of DNA damage, e.g. as a result of Xradiation or chemotherapy (Lowe et al., 1993) . Moreover, wild-type p53 has recently been reported to play a role in the induction of apoptosis by growth factor deprivation (Zhu et al., 1994) , possibly by down-regulating Bcl-2 and upregulating Bax protein expresson (Haldar et al., 1994; Miyashita et al., 1994) . It has been reported that BT-474 cells bear a missense mutation in the p53 gene and show loss of heterozygosity (Bartek et al., 1990 ) at this locus. The effect of absence of wild-type p53 in this cell lie on cell death regulation therefore needs further clarification.
In conclusion, BT-474 cells offer an interesting opportunity to investigate various aspects of growth regulation and dissemination in oestrogen-dependent breast cancer. Moreover, the capacity of this cell lne to grow and metastasise in immune-deficient mice in combination with high expression of oell-surface proteins such as c-ErbB-2 and esialin make it a potentially usefu in vitro/in vivo model for research in immune therapy.
